Retefast 18mg Injection
Marketer
Cipla Ltd
Salt Composition
Reteplase (18mg)
Overview Retefast 18mg Injection
Thrombolytic agent Retefast, an 18mg injectable solution, rapidly disintegrates blood clots obstructing blood vessels. Its primary application is acute myocardial infarction (heart attack) treatment, restoring blood flow to compromised cardiac tissue and mitigating potential necrosis. Administered intravenously by a physician immediately upon the onset of heart attack symptoms, its effects are closely monitored, including vital signs (respiration, blood pressure, oxygen saturation). Concurrently, or subsequently, anticoagulants may be prescribed. Increased bleeding risk necessitates caution with sharp objects (e.g., razors, nail clippers). Potential side effects include nausea, vomiting, hypotension, and injection site hemorrhage. Due to its complex administration requirements and contraindications, Retefast is exclusively administered by healthcare professionals. Its use is contraindicated in numerous situations, notably recent head trauma or neurosurgery, and any active bleeding. A thorough medical history review is mandatory prior to treatment.
Uses of Retefast 18mg Injection
Myocardial infarction
Major Benefits of Retefast 18mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Retefast 18mg Injection:
- Bleeding disorder
- Nausea
- Vomiting
- Decreased blood pressure
- Injection site bleeding
How to use Retefast 18mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
How Retefast 18mg Injection works:
Thrombolytic agent Retefast, administered via 18mg injection, disintegrates obstructive blood clots within the vasculature. This action facilitates restored blood flow to compromised tissues, mitigating tissue necrosis and improving patient prognosis.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Retefast 18mg Injection may pose unknown risks. Physician consultation is advised.
PregnancyCONSULT YOUR DOCTOR
The use of Retefast 18mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Administration of Retefast 18mg Injection while breastfeeding appears to pose minimal risk. Available human data indicate negligible danger to the infant.
DrivingNOT RELEVANT
Retefast 18mg Injection is exclusively for inpatient administration.
KidneyCAUTION
Patients with impaired kidney function should use Retefast 18mg Injection cautiously, potentially requiring a modified dosage. Physician consultation is advised. Retefast 18mg Injection is contraindicated in individuals with severely compromised kidney function.
LiverCAUTION
Individuals with liver impairment should use Retefast 18mg Injection cautiously, potentially requiring dosage modification. Medical advice is recommended. Retefast 18mg Injection is unsuitable for patients exhibiting severe kidney dysfunction.
What if you forget to take Retefast 18mg Injection :
NA
Facts to Know About Retefast 18mg Injection
| Label | Value |
|---|---|
| Chemical Category | Carboxylic Acid Derivatives |
| Developing Habits | No. |
| Treatment Category | Heart |
| Action Class | Thrombolytic Agents (Plasminogen Activators) |
3,018 People bought this recently